TARSUS PHARMACEUTICALS, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
TARSUS PHARMACEUTICALS, INC. (TARS) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 6.21 million shares for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-31.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-03-31
- TARSUS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 16.80M shares, a 567.71% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 2.73M shares, a 10.46% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2019-12-31 was 2.52M shares.
- TARSUS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2019-09-30 was 2.47M shares.
- TARSUS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 6.21M shares, a 162.72% increase from fiscal 2019.
- TARSUS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 2.36M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2020-12-31 | 16.80M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | 9.76M shares derived: average of 2 quarters · filed 2021-03-31 | 6.21M shares 10-K · filed 2021-03-31 | |
| 2020-09-30 | 2.73M shares 10-Q · filed 2020-11-25 | 2.68M shares 10-Q · filed 2020-11-25 | ||
| 2019-12-31 | 2.52M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | 2.49M shares derived: average of 2 quarters · filed 2021-03-31 | 2.36M shares 10-K · filed 2021-03-31 | |
| 2019-09-30 | 2.47M shares 10-Q · filed 2020-11-25 | 2.31M shares 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |